18F-FDG PET Imaging of Myocardial Viability in an Experienced Center with Access to 18F-FDG and Integration with Clinical Management Teams: The Ottawa-FIVE Substudy of the PARR 2 Trial

被引:108
|
作者
Abraham, Arun [1 ,2 ]
Nichol, Graham [3 ]
Williams, Kathryn A. [1 ,2 ]
Guo, Ann [1 ,2 ]
deKemp, Robert A. [1 ,2 ]
Garrard, Linda [1 ,2 ]
Davies, Ross A. [1 ,2 ]
Duchesne, Lloyd [1 ,2 ]
Haddad, Haissam [1 ,2 ]
Chow, Benjamin [1 ,2 ]
DaSilva, Jean [1 ,2 ]
Beanlands, Rob S. B. [1 ,2 ]
机构
[1] Univ Ottawa, Inst Heart, Natl Cardiac PET Ctr, Ottawa, ON K1Y 4W7, Canada
[2] Univ Ottawa, Inst Heart, Div Cardiol, Cardiovasc Res Methods Ctr, Ottawa, ON K1Y 4W7, Canada
[3] Univ Washington, Harborview Ctr Prehosp Emergency Care, Seattle, WA 98195 USA
关键词
cardiology (clinical); PET; fluorodeoxyglucose; LV dysfunction; viability; LEFT-VENTRICULAR DYSFUNCTION; POSITRON-EMISSION-TOMOGRAPHY; CORONARY-ARTERY-DISEASE; RANDOMIZED-TRIALS; REVASCULARIZATION; PROGNOSIS; MORTALITY; SUBGROUP; INFARCTION; SURVIVAL;
D O I
10.2967/jnumed.109.065938
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
F-18-FDG PET may assist decision making in ischemic cardiomyopathy. The PET and Recovery Following Revascularization (PARR 2) trial demonstrated a trend toward beneficial outcomes with PET-assisted management. The substudy of PARR 2 that we call Ottawa-FIVE, described here, was a post hoc analysis to determine the benefit of PET in a center with experience, ready access to F-18-FDG, and integration with clinical teams. Methods: Included were patients with left ventricular dysfunction and suspected coronary artery disease being considered for revascularization. The patients had been randomized in PARR 2 to PET-assisted management (group 1) or standard care (group 2) and had been enrolled in Ottawa after August 1, 2002 (the date that on-site F-18-FDG was initiated) (n = 111). The primary outcome was the composite endpoint of cardiac death, myocardial infarction, or cardiac rehospitalization within 1 y. Data were compared with the rest of PARR 2 (PET-assisted management [group 3] or standard care [group 4]). Results: In the Ottawa-FIVE subgroup of PARR 2, the cumulative proportion of patients experiencing the composite event was 19% (group 1), versus 41% (group 2). Multivariable Cox proportional hazards regression showed a benefit for the PET-assisted strategy (hazard ratio, 0.34; 95% confidence interval, 0.16-0.72; P = 0.005). Compared with other patients in PARR 2, Ottawa-FIVE patients had a lower ejection fraction (25% +/- 7% vs. 27% +/- 8%, P = 0.04), were more often female (24% vs. 13%, P = 0.006), tended to be older (64 +/- 10 y vs. 62 +/- 10 y, P = 0.07), and had less previous coronary artery bypass grafting (13% vs. 21%, P = 0.07). For patients in the rest of PARR 2, there was no significant difference in events between groups 3 and 4. The observed effect of F-18-FDG PET-assisted management in the 4 groups in the context of adjusted survival curves demonstrated a significant interaction (P = 0.016). Comparisons of the 2 arms in Ottawa-FIVE to the 2 arms in the rest of PARR 2 demonstrated a trend toward significance (standard care, P = 0.145; PET-assisted management, P = 0.057). Conclusion: In this post hoc group analysis, a significant reduction in cardiac events was observed in patients with F-18-FDG PET-assisted management, compared with patients who received standard care. The results suggest that outcome may be benefited using F-18-FDG PET in an experienced center with ready access to F-18-FDG and integration with imaging, heart failure, and revascularization teams.
引用
收藏
页码:567 / 574
页数:8
相关论文
共 50 条
  • [1] 18F-FDG PET and Myocardial Viability Assessment: Trials and Tribulations
    Allman, Kevin C.
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (04) : 505 - 506
  • [2] MANAGEMENT PRINCIPLES OF INCIDENTAL THYROID 18F-FDG UPTAKE IDENTIFIED ON 18F-FDG PET/CT IMAGING
    Akbas, A.
    Dagmura, H.
    Gul, S.
    Dasiran, F.
    Daldal, E.
    Okan, I
    ACTA ENDOCRINOLOGICA-BUCHAREST, 2022, 18 (02) : 253 - 257
  • [3] 18F-FDG PET/CT in the Management of Aortitis
    Bruls, Samuel
    Courtois, Audrey
    Nusgens, Betty
    Defraigne, Jean-Olivier
    Delvenne, Philippe
    Hustinx, Roland
    Moutschen, Michel
    Sakalihasan, Natzi
    CLINICAL NUCLEAR MEDICINE, 2016, 41 (01) : 28 - 33
  • [4] 18F-FDG PET/CT for the Assessment of Myocardial Sarcoidosis
    Skali, Hicham
    Schulman, Allison R.
    Dorbala, Sharmila
    CURRENT CARDIOLOGY REPORTS, 2013, 15 (04)
  • [5] 18F-FDG PET/MRI and 18F-FDG PET/CT for the Management of Gynecological Malignancies: A Comprehensive Review of the Literature
    Allahqoli, Leila
    Hakimi, Sevil
    Lagana, Antonio Simone
    Momenimovahed, Zohre
    Mazidimoradi, Afrooz
    Rahmani, Azam
    Fallahi, Arezoo
    Salehiniya, Hamid
    Ghiasvand, Mohammad Matin
    Alkatout, Ibrahim
    JOURNAL OF IMAGING, 2023, 9 (10)
  • [6] 18F-FDG PET/CT Imaging In Oncology
    Almuhaideb, Ahmad
    Papathanasiou, Nikolaos
    Bomanji, Jamshed
    ANNALS OF SAUDI MEDICINE, 2011, 31 (01) : 3 - 13
  • [7] 18F-FDG PET in Myocardial Viability Assessment: A Practical and Time-Efficient Protocol
    Mhlanga, Joyce
    Derenoncourt, Paul
    Haq, Adeel
    Bhandiwad, Anita
    Laforest, Richard
    Siegel, Barry A.
    Dehdashti, Farrokh
    Gropler, Robert J.
    Schindler, Thomas H.
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (04) : 602 - 608
  • [8] Acquisition, Processing, and Interpretation of PET 18F-FDG Viability and Inflammation Studies
    Celiker-Guler, Emel
    Ruddy, Terrence D.
    Wells, R. Glenn
    CURRENT CARDIOLOGY REPORTS, 2021, 23 (09)
  • [9] 18F-FDG PET/CT in the Management of Osteosarcoma
    Oh, Chiwoo
    Bishop, Michael W.
    Cho, Steve Y.
    Im, Hyung-Jun
    Shulkin, Barry L.
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (06) : 842 - 851
  • [10] 18F-FDG PET imaging of muscle activity in runners
    Tashiro, M
    Fujimoto, T
    Itoh, M
    Kubota, K
    Fujiwara, T
    Miyake, M
    Watanuki, S
    Horikawa, E
    Sasaki, H
    Ido, T
    JOURNAL OF NUCLEAR MEDICINE, 1999, 40 (01) : 70 - 76